Allogene Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.0K | $95.0K | $156.0K | $114.1M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M |
| SG&A Expense | $56.8M | $65.2M | $71.7M | $79.3M | $74.1M | $65.3M | $57.5M |
| Operating Income | $-209.3M | $-273.2M | $-327.7M | $-335.5M | $-180.2M | $-258.2M | $-202.0M |
| Operating Margin | — | -1,241,813.6% | -344,986.3% | -215,087.2% | -157.9% | — | — |
| Interest Expense | — | — | — | — | — | $0 | $0 |
| Pretax Income | $-190.9M | $-257.1M | $-327.3M | — | $-257.0M | $-250.2M | $-184.9M |
| Income Tax Expense | $0 | $443.0K | $0 | $0 | $0 | $0 | $-331.0K |
| Net Income | $-190.9M | $-257.6M | $-327.3M | $-340.4M | $-182.1M | $-316.4M | $-184.6M |
| Net Margin | — | -1,170,863.6% | -344,489.5% | -218,214.1% | -159.6% | — | — |
| EPS (Basic) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.63 | $-1.83 |
| EPS (Diluted) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.63 | $-1.83 |
| Shares Outstanding (Basic) | 220.6M | 194.8M | 156.9M | 143.1M | 135.8M | 120.4M | 101.1M |
| Shares Outstanding (Diluted) | 220.6M | 194.8M | 156.9M | 143.1M | 135.8M | 120.4M | 101.1M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |